1 / 30

Taking Care of the Whole Child

Taking Care of the Whole Child. Robbyn E Sockolow, MD Associate Professor of Clinical Pediatrics Director of Pediatric Gastroenterology New York Presbyterian- Weill Cornell Medical Center. Health Supervision: Outline. Growth and nutrition Disease activity Prevention and surveillance

koen
Télécharger la présentation

Taking Care of the Whole Child

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Taking Care of the Whole Child Robbyn E Sockolow, MD Associate Professor of Clinical Pediatrics Director of Pediatric Gastroenterology New York Presbyterian- Weill Cornell Medical Center

  2. Health Supervision: Outline • Growth and nutrition • Disease activity • Prevention and surveillance • Psychosocial well being

  3. Health Supervision: Outline • Growth and nutrition • Height, Weight, BMI, Bone Health • Disease activity • Mission = Remission • Prevention and surveillance • Vaccinations • Cancer screening • Psychosocial well being • Screening for anxiety/depression

  4. Areas of supervision • Vaccination Status • Vitamin Status • Bone Health • Ophthalmologic health • Dermatologic health • Annual PPD

  5. Vaccines

  6. Immunosuppression: • Treatment with glucocorticoids (prednisone 20 mg/d equivalent, or 2 mg/kg/d if less than 10 kg, for 2 weeks or more, and within 3 months of stopping). • Treatment with effective doses of 6-mercaptopurine/azathioprine (effect on safety not established) and within 3 months of stopping. • Treatment with methotrexate (effect on safety not established) and within 3 months of stopping. • Treatment with infliximab/adalimumab (effect on safety not established) and within 3 months of stopping. • Significant protein-calorie malnutrition. Sands et al Inflamm Bowel Dis2004;10:677

  7. Vaccines that are killed and considered safe • IM/SC influenza vaccine • Hepatitis A and B vaccine • Meningococcal vaccine • Human Papilloma virus vaccine • Pneumovax

  8. Live Vaccines • Smallpox vaccine • Tuberculosis BCG vaccine • Typhoid live oral vaccine • Varicella • Yellow fever • Anthrax vaccine • Intranasal influenza • Measles-mumps-rubella (MMR) • Polio live oral vaccine (OPV) • Rotavirus (oral)

  9. Proportion of subjects achieving a post-vaccination of Pneumococcal Polysaccharide Vaccine geometric mean titer (GMT) 1 μ g / 100 Melmed G et al. Am J Gastroenterol 2010; 105:148–154

  10. Pediatric IBD: Health Screening • Confirm vaccine efficacy at diagnosis • Maximizes time available to immunize • Titers for Varicella, Hepatitis BsAb and Hepatitis A IgG, MMR?? • PPD at diagnosis • Confirm before biologics

  11. Vaccines in Pediatric IBD:Continue Inactivated Vaccinations Inactivated vaccines—stay on schedule • Tetanus, Diphtheria, Pertussis (DPT) • Human Papilloma virus (HPV) • Influenza (injectable only) • Pneumococcal • Hepatitis A and Hepatitis B • Meningococcal Melmed GY. Inflamm Bowel Dis 2009;15:1410–1416. Wasan SK et al., Clin Gastroenterol Hepatol 2010;8:1013–1016

  12. Limit Live/Attenuated Vaccinations NO live or attenuated vaccines if taking IM/Biologics • Measles mumps rubella (MMR) – wait 6 weeks • Varicella (titer at diagnosis) – wait 4-12 weeks • Intranasal influenza • Oral polio • Smallpox • Yellow Fever Melmed GY. Inflamm Bowel Dis 2009;15:1410–1416. Wasan SK et al., Clin Gastroenterol Hepatol 2010;8:1013–1016

  13. Travel Related Live/Attenuated Vaccines • Anthrax • Bacillus Calmette Guérin (BCG) • Smallpox • Oral Typhoid • Yellow Fever

  14. Pediatric IBD: Limits onLive/Attenuated Vaccinations • Consider immunization before initiation of immunosuppressive therapy • Consider checking post-vaccine titers Melmed GY. Inflamm Bowel Dis 2009;15:1410–1416. Wasan SK et al., Clin Gastroenterol Hepatol 2010;8:1013–1016

  15. Bone health

  16. Pediatric IBD: Bones at Risk • At risk for decreased bone mass • Often present at diagnosis (disease related) • Can be acquired over time (treatment related) • Potential for increase in fracture risk • Vertebral and long bone Pappa H, et al. J Pediatr Gastroenterol Nutr 2011;53:11–25 Sylvester FA, et al. Inflamm Bowel Dis 2007;13:42-50

  17. Vitamin D3 & Crohn’s Disease: Manitoba IBD Registry Increased prevalence of vitamin D deficiency in Inflammatory bowel disease Leslie WD, Miller N, Rogala L, Bernstein CN. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. AJG. 2008 Jun;103(6)

  18. Loss of trabecular plates results in weakened bone structure significantly increasing risk of fractures. Normal Bone vs Osteoporotic Bone 75 yo normal woman 47 yo s/p multiple vertebral compression fractures

  19. DEXA Screening for Bone Health:Pediatric Pearls • Order total body (minus skull) • Need a pediatric experienced site! • Age and sex adjusted Z scores (not T-scores!) • Patient size affects the test—may have to adjust • Interpretation • Z-score < ‐2.0 = significant deficit • Z-score < -1.0 = monitor closely Pappa H, et al. J Pediatr Gastroenterol Nutr 2011;53:11–25 Lewiecki EM, et al. Bone 2008;43:1115-1121

  20. Fewtrell et al, Bone densitometry in children assessed by dual x ray absorptiometry: uses and pitfalls Arch Dis Child 2003: 88; 795-798

  21. Pediatric IBD:When to Obtain DEXA • Recommended at diagnosis • Repeat “when clinically indicated” • Slowed growth velocity (height z-score <2) • Previous BMD z-score < -1 • Delayed puberty or amenorrhea • Severe course especially if low albumin • Prolonged steroid use (> 6 months) Pappa H, et al. J Pediatr Gastroenterol Nutr 2011;53:11–25

  22. Bone in Pediatric IBD: Therapy • Control inflammation • Optimize nutrition • Monitor growth and development (menses) • Weight-bearing activity • Optimize Vitamin D/calcium status • Specialist if complication occurs • e.g. Compression fracture Pappa H, et al. J Pediatr Gastroenterol Nutr 2011;53:11–25

  23. Vitamin D in Pediatric IBD • Deficiency in >30% of pediatric IBD patients • Higher risk: Darker complexion, active disease • Measure yearly 25-OH level: Later winter/spring • Keep level > 32 ng/mL • 800 to 1,000 IU/day as maintenance (D3) • Supplement Calcium 1,000—1,600mg a day Pappa H, et al. Pediatrics 2006;118:1950 -1961 Pappa H, et al. J Pediatr Gastroenterol Nutr 2011;53:11–25

  24. Cancer Prevention

  25. Pediatric IBD: Cancer Screening • Skin cancer • 1o prevention (hats, sunglasses, SPF > 30) • Yearly dermatologic screening • Especially if using immunomodulators/Biologics • Articles for both Thiopurines and Biologics in Rheum literature Peyrin-Biroulet et al Gastro 2011 Cesame Group Nancy France Long MD, et al. Inflamm Bowel Dis 2011;17:1423-1427 Rubenstein et al. Am J Gastroenterol2009;104:2222-2232 Kramagar et al J Dermat Treat UCSF 2012

  26. Pediatric IBD: Cancer Screening • Colonoscopy • Screen 7-10 yrs if colonic disease diagnosed • Yearly if diagnosed with PSC • Surveillance every 1-2 subsequent years • Pouchoscopy and cuff biopsies after IPAA

  27. Mental health

  28. Assessing Psychosocial Wellness • Situational distress vs prolonged functional impairment • 25% develop anxiety and/or depression • Frequent follow up visits allow screening • Adherence and psychosocial wellness • Focus on the child/ adolescent Mackner LM, et al. Inflamm Bowel Dis 2006;12:239-244 Engstrom I. J Child Psychol Psychiatry 1992;33:563-582 Szigethy E, et al. J Pediatr Gastroenterol Nutr 2004;39:395-403

  29. Intervention:Depression/Anxiety • Appropriate referral to a mental health professional • Cognitive behavioral therapy (CBT): best evidence for treating anxiety, depression Szigethy E, et al. Child Adolesc Psychiatr Clin N Am 2010;19:301-318

  30. Psychosocial Intervention: Pediatric IBD • Therapeutic relationship • Support groups, CCFA camp • ? Role of self-management programs • ?Role of social networks/websites Shepanski MA, et al. Inflamm Bowel Dis 2005;11:164–170 Szigethy E, et al. Inflamm Bowel Dis 2009;15:1127-1128

More Related